Antipsychotic drugs and obesity:: Is prolactin involved?
Antipsychotic drugs and obesity:: Is prolactin involved?
复制标题
DOI：
10.1177/070674370104600906
复制
发表时间：
2001-11-01
影响因子：
4
通讯作者：
Hernàndez, L
中科院分区：
文献类型：
--
作者：
Baptista, T;Lacruz, A;Hernàndez, L
目的：将接受典型抗精神病药物 (AP) 药物治疗的异质患者群体中的人体测量指数（体重指数 [BMI] 和腰臀比 [WHR]）与血清催乳素水平相关联。方法：我们评估了接受 APS 治疗的住院患者 (n = 105) 和门诊患者 (n = 122) 以及接受其他精神药物的门诊患者的 BM、WHR 和空腹血清催乳素水平（OPD）（n = 77），以及无药物受试者（n = 33）。门诊患者可以自由获取食物，而住院患者样本由每日大约 2000 Kcal 饮食单调的人群组成。 结果：催乳素与整个接受 AP 治疗的门诊男性组的 BM 呈正相关（P = 0.03），并且与接受 AP 治疗的住院男性的 WHR 呈正相关（P = 0.053）。关于治疗持续时间，连续治疗超过 1 年的男性中催乳素和 BM 呈正相关（P = 0.023）。相比之下，在接受 AP 治疗的门诊女性中观察到催乳素与 BMI 之间呈负相关趋势 (P = 0.08)。在其他组中没有观察到显着的相关性，甚至没有观察到趋势。结论：催乳素可能与 AP 引起的体重增加有关，特别是在男性中。未来的研究应该描述 AP 治疗期间催乳素对体重影响最大的时期。还可以识别对高催乳素血症特别敏感的特定人群。在接受 AP 治疗的女性中检测到的催乳素与 BMI 之间的负相关性类似于在严重原发性肥胖中观察到的催乳素反应减弱。
Objectives: To correlate the anthropometric indexes (Body Mass Index [BMI] and Waist-Hip ratio [WHR]) with the serum pro-lactin levels in a heterogeneous population of patients treated with typical antipsychotic (AP) drugs.Methods: We evaluated BM, WHR, and fasting serum prolactin of inpatients (n = 105) and outpatients (n = 122) treated with APS, in outpatients receiving other psychotropic drugs (OPDs) (n = 77), and in drug-free subjects (n = 33). Outpatients had free access to food, whereas the inpatient sample comprised people with a monotonous diet of approximately 2000 Kcal daily.Results: Prolactin correlated positively with the BM in the whole group of AP-treated outpatient men (P = 0.03) and with the WHR in AP-treated inpatient men (P = 0.053). Regarding treatment duration, prolactin and BM correlated positively in men consecutively treated for more than 1 year (P = 0.023). By contrast, a trend toward a negative correlation between prolactin and BMI was observed in AP-treated outpatient women (P = 0.08). No significant correlation, or even a trend, was observed in the other groups.Conclusions: Prolactin may be involved in AP-induced weight gain, particularly in men. Future studies should characterize thc period of maximal prolactin impact on body weight during AP treatment. Specific populations particularly sensitive to hyperprolactinemia might be identified as well. The negative correlation between prolactin and BMI detected in AP-treated women resembles the dampened prolactin response observed in severe primary obesity.